Kimberlee C. Drapkin

CIK: 0001340881

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (8.3%)

Derivative conversions

Awards (A)9 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

LENZ

LENZ Therapeutics, Inc.

Director

CLYM

Climb Bio, Inc.

Director

ABOS

Acumen Pharmaceuticals, Inc.

Director

KINETA, INC./DE

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

LENZ
LENZ Therapeutics, Inc.
Jun 15, 2026
Award(A)
Stock Option (right to buy)
Direct
22.1K shares-
CLYM
Climb Bio, Inc.
Jun 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jun 3, 2026
Award(A)
Direct
35.5K shares-
KANT
KINETA, INC./DE
Jun 30, 2025
Disposition(D)
Direct
13.8K shares-
KANT
KINETA, INC./DE
Jun 25, 2025
Award(A)
Direct
6K shares-
KANT
KINETA, INC./DE
Jun 23, 2025
Tax Payment(F)
Direct
4.7K shares at avg. $0.26$1K
KANT
KINETA, INC./DE
Jun 23, 2025
Exercise(M)
Direct
12.5K shares at avg. $0.61$8K
LENZ
LENZ Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (right to buy)
Direct
13.5K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jun 4, 2025
Award(A)
Direct
12.8K shares-
CLYM
Climb Bio, Inc.
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
CLYM
Climb Bio, Inc.
Mar 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-
KA
KINETA, INC./DE
Sep 4, 2024
Award(A)
Stock Option (Right to Buy)
Direct
12.5K shares-

		Type	Shares	Price		Ownership
Jun 15, 2026	LENZ LENZ Therapeutics, Inc.	Award(A) Stock Option (right to buy)	22,100	-	-	Direct
Jun 5, 2026	CLYM Climb Bio, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Jun 3, 2026	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	35,500	-	$0	Direct
Jun 30, 2025	KANT KINETA, INC./DE	Disposition(D)	13,794	-	-	Direct
Jun 25, 2025	KANT KINETA, INC./DE	Award(A)	6,000	-	-	Direct
Jun 23, 2025	KANT KINETA, INC./DE	Tax Payment(F)	4,706	$0.26	$1,224	Direct
Jun 23, 2025	KANT KINETA, INC./DE	Exercise(M)	12,500	$0.61	$7,638	Direct
Jun 11, 2025	LENZ LENZ Therapeutics, Inc.	Award(A) Stock Option (right to buy)	13,500	-	-	Direct
Jun 4, 2025	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	12,800	-	-	Direct
Jun 4, 2025	CLYM Climb Bio, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Mar 28, 2025	CLYM Climb Bio, Inc.	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct
Sep 4, 2024	KA KINETA, INC./DE	Award(A) Stock Option (Right to Buy)	12,500	-	-	Direct

1-12 of 12 transactions

About Drapkin Kimberlee C

Drapkin Kimberlee C (SEC CIK 0001340881) files insider reports with the SEC as Director of LENZ Therapeutics, Inc. (LENZ), Director of Climb Bio, Inc. (CLYM) and Director of Acumen Pharmaceuticals, Inc. (ABOS). Signal8 also holds filings tied to 1 other company.

Signal8 holds 11 ownership filings by Drapkin Kimberlee C (1 Form 3, 10 Form 4), filed between Sep 5, 2024 and Jun 15, 2026. Those filings report 12 transactions, from Sep 4, 2024 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Drapkin Kimberlee C's filings is in NEWTON, MA.

Recent filings by Drapkin Kimberlee C

Jun 15, 2026: Grant or award of LENZ derivative securities (Form 4, code A).
Jun 5, 2026: Grant or award of CLYM derivative securities (Form 4, code A).
Jun 3, 2026: Grant or award of ABOS shares (Form 4, code A).
Jun 30, 2025: Disposition to issuer transaction of KANT shares (Form 4, code D).
Jun 25, 2025: Grant or award of KANT shares (Form 4, code A).

Other insiders filing for LENZ Therapeutics, Inc. (LENZ)

How to read Form 4 transaction codes